Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 0.63
PRXL's Cash to Debt is ranked lower than
69% of the 211 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.29 vs. PRXL: 0.63 )
Ranked among companies with meaningful Cash to Debt only.
PRXL' s Cash to Debt Range Over the Past 10 Years
Min: 0.17  Med: 8.45 Max: No Debt
Current: 0.63
Equity to Asset 0.33
PRXL's Equity to Asset is ranked lower than
80% of the 192 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.59 vs. PRXL: 0.33 )
Ranked among companies with meaningful Equity to Asset only.
PRXL' s Equity to Asset Range Over the Past 10 Years
Min: 0.27  Med: 0.45 Max: 0.72
Current: 0.33
0.27
0.72
Interest Coverage 25.19
PRXL's Interest Coverage is ranked lower than
58% of the 139 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 77.70 vs. PRXL: 25.19 )
Ranked among companies with meaningful Interest Coverage only.
PRXL' s Interest Coverage Range Over the Past 10 Years
Min: 3.16  Med: 6.29 Max: 28.15
Current: 25.19
3.16
28.15
F-Score: 9
Z-Score: 3.67
M-Score: -2.56
WACC vs ROIC
6.18%
20.24%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 9/10

vs
industry
vs
history
Operating margin (%) 10.00
PRXL's Operating margin (%) is ranked higher than
70% of the 197 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.14 vs. PRXL: 10.00 )
Ranked among companies with meaningful Operating margin (%) only.
PRXL' s Operating margin (%) Range Over the Past 10 Years
Min: 5.49  Med: 6.55 Max: 9.23
Current: 10
5.49
9.23
Net-margin (%) 6.94
PRXL's Net-margin (%) is ranked higher than
73% of the 197 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.64 vs. PRXL: 6.94 )
Ranked among companies with meaningful Net-margin (%) only.
PRXL' s Net-margin (%) Range Over the Past 10 Years
Min: 3.11  Med: 4.44 Max: 6.38
Current: 6.94
3.11
6.38
ROE (%) 28.70
PRXL's ROE (%) is ranked higher than
94% of the 189 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -4.49 vs. PRXL: 28.70 )
Ranked among companies with meaningful ROE (%) only.
PRXL' s ROE (%) Range Over the Past 10 Years
Min: 9.33  Med: 14.95 Max: 23.85
Current: 28.7
9.33
23.85
ROA (%) 8.51
PRXL's ROA (%) is ranked higher than
84% of the 213 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -4.98 vs. PRXL: 8.51 )
Ranked among companies with meaningful ROA (%) only.
PRXL' s ROA (%) Range Over the Past 10 Years
Min: 3.4  Med: 5.96 Max: 7.99
Current: 8.51
3.4
7.99
ROC (Joel Greenblatt) (%) 53.80
PRXL's ROC (Joel Greenblatt) (%) is ranked higher than
84% of the 212 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -9.85 vs. PRXL: 53.80 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
PRXL' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: 21.14  Med: 42.99 Max: 58.04
Current: 53.8
21.14
58.04
Revenue Growth (3Y)(%) 10.10
PRXL's Revenue Growth (3Y)(%) is ranked higher than
73% of the 140 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.50 vs. PRXL: 10.10 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
PRXL' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 5.3  Med: 13.9 Max: 19.1
Current: 10.1
5.3
19.1
EBITDA Growth (3Y)(%) 18.90
PRXL's EBITDA Growth (3Y)(%) is ranked higher than
79% of the 127 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.80 vs. PRXL: 18.90 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
PRXL' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -11.3  Med: 14.2 Max: 56.4
Current: 18.9
-11.3
56.4
EPS Growth (3Y)(%) 21.10
PRXL's EPS Growth (3Y)(%) is ranked higher than
78% of the 118 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.00 vs. PRXL: 21.10 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
PRXL' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -32.8  Med: 21.1 Max: 40.6
Current: 21.1
-32.8
40.6
» PRXL's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q4 2015

PRXL Guru Trades in Q4 2015

George Soros 5,800 sh (New)
Ken Fisher 2,355,456 sh (-1.58%)
Chuck Royce 313,300 sh (-4.01%)
Jim Simons 371,000 sh (-38.36%)
Vanguard Health Care Fund 2,015,640 sh (-41.52%)
Joel Greenblatt 316,310 sh (-55.56%)
» More
Q1 2016

PRXL Guru Trades in Q1 2016

Steven Cohen 69,900 sh (New)
Paul Tudor Jones 8,000 sh (New)
George Soros Sold Out
Joel Greenblatt Sold Out
Ken Fisher 2,336,981 sh (-0.78%)
Chuck Royce 300,800 sh (-3.99%)
Vanguard Health Care Fund 1,836,340 sh (-8.90%)
Jim Simons 146,700 sh (-60.46%)
» More
Q2 2016

PRXL Guru Trades in Q2 2016

Ken Fisher 2,337,002 sh (unchged)
Jim Simons Sold Out
Chuck Royce 293,600 sh (-2.39%)
Vanguard Health Care Fund 1,168,440 sh (-36.37%)
Paul Tudor Jones 4,800 sh (-40.00%)
Steven Cohen 20,200 sh (-71.10%)
» More
Q3 2016

PRXL Guru Trades in Q3 2016

Joel Greenblatt 64,743 sh (New)
Steven Cohen 103,800 sh (+413.86%)
Chuck Royce 293,600 sh (unchged)
Vanguard Health Care Fund 1,168,440 sh (unchged)
Paul Tudor Jones Sold Out
Ken Fisher 2,312,019 sh (-1.07%)
» More
» Details

Insider Trades

Latest Guru Trades with PRXL

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research
Compare:NAS:PRAH, NYSE:ALR, NYSE:CRL, NAS:INCR, NAS:VWR, OTCPK:CZMWY, NAS:BRKR, NAS:NEOG, NAS:CPHD, NAS:ICLR, NAS:EXAS, NAS:MEDP, NAS:AXDX, NAS:ABAX, NAS:MYGN, NAS:ALOG, NYSE:BIO.B, NAS:KANG, NAS:GHDX, NAS:FMI » details
Traded in other countries:PAX.Germany,
Parexel International Corp is a biopharmaceutical services company. The Company offers clinical research, clinical logistics, medical communications, and technology products and services to the pharmaceutical, biotechnology, and medical device industries.

Parexel International Corp was incorporated in 1983. The Company provides clinical research, medical communications, consulting, commercialization and informatics and technology services to the pharmaceutical, biotechnology, and medical device industries. The Company has three reporting segments: Clinical Research Services (CRS), PAREXEL Consulting and Medical Communications Services (PCMS), and Perceptive Informatics (Perceptive). CRS constitutes its core business and include all phases of clinical research from first-in-man trials, where a medicinal entity is tested on human subjects for the first time, through post-marketing studies, following approval by the presiding regulatory body. CRS service offerings include clinical trials management, observational studies, patient/disease registries and post-marketing surveillance, data management and biostatistics, epidemiology and health economics/outcomes research, clinical logistics, pharmacovigilance, and clinical pharmacology, as well as related medical affairs, patient recruitment, and investigator site services. PCMS provides technical expertise and advice in such areas as drug development, regulatory affairs, and good manufacturing practice (GMP) compliance consulting. In addition, PCMS provides a full spectrum of market development, product development, commercialization, and targeted communications services in support of product launch. PCMS consultants also identify alternatives and propose solutions to address clients' product development, registration, and commercialization issues. Additionally, PCMS provides reimbursement and market access (RMA) services. Perceptive provides information technology solutions designed to improve clients' product development processes. Perceptive's portfolio of products and services includes ClinPhone RTSM, medical imaging services, CTMS, EDC, web-based portals, systems integration, and patient diary applications. These solutions are sold individually or in combination, as elements of an eClinical suite. It competes with other biopharmaceutical services companies and other clinical research organizations (CROs) that provide one or more of the services being offered by it. Some of the biopharmaceutical services companies, such as Quintiles Transnational Corporation, Covance Inc., Pharmaceutical Product Development Inc., inVentiv Health, INC Research, and Icon plc, offer services that compete directly with its services at many levels.

Ratios

vs
industry
vs
history
P/E(ttm) 18.83
PRXL's P/E(ttm) is ranked higher than
75% of the 120 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 31.96 vs. PRXL: 18.83 )
Ranked among companies with meaningful P/E(ttm) only.
PRXL' s P/E(ttm) Range Over the Past 10 Years
Min: 6.5  Med: 26.17 Max: 42.45
Current: 18.83
6.5
42.45
Forward P/E 15.67
PRXL's Forward P/E is ranked higher than
81% of the 47 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 20.70 vs. PRXL: 15.67 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 18.83
PRXL's PE(NRI) is ranked higher than
78% of the 108 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 32.55 vs. PRXL: 18.83 )
Ranked among companies with meaningful PE(NRI) only.
PRXL' s PE(NRI) Range Over the Past 10 Years
Min: 6.5  Med: 26.12 Max: 42.45
Current: 18.83
6.5
42.45
Price/Owner Earnings (ttm) 17.76
PRXL's Price/Owner Earnings (ttm) is ranked higher than
78% of the 63 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 27.54 vs. PRXL: 17.76 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
PRXL' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 9.66  Med: 23.99 Max: 475.93
Current: 17.76
9.66
475.93
P/B 4.51
PRXL's P/B is ranked lower than
63% of the 232 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.35 vs. PRXL: 4.51 )
Ranked among companies with meaningful P/B only.
PRXL' s P/B Range Over the Past 10 Years
Min: 0.98  Med: 3.38 Max: 8
Current: 4.51
0.98
8
P/S 1.31
PRXL's P/S is ranked higher than
80% of the 228 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.20 vs. PRXL: 1.31 )
Ranked among companies with meaningful P/S only.
PRXL' s P/S Range Over the Past 10 Years
Min: 0.33  Med: 1.14 Max: 1.77
Current: 1.31
0.33
1.77
PFCF 16.77
PRXL's PFCF is ranked higher than
69% of the 77 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 22.43 vs. PRXL: 16.77 )
Ranked among companies with meaningful PFCF only.
PRXL' s PFCF Range Over the Past 10 Years
Min: 9.42  Med: 20.65 Max: 3775
Current: 16.77
9.42
3775
POCF 11.63
PRXL's POCF is ranked higher than
73% of the 96 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 17.33 vs. PRXL: 11.63 )
Ranked among companies with meaningful POCF only.
PRXL' s POCF Range Over the Past 10 Years
Min: 5.13  Med: 14.49 Max: 2776
Current: 11.63
5.13
2776
EV-to-EBIT 13.74
PRXL's EV-to-EBIT is ranked higher than
77% of the 118 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 22.82 vs. PRXL: 13.74 )
Ranked among companies with meaningful EV-to-EBIT only.
PRXL' s EV-to-EBIT Range Over the Past 10 Years
Min: 5.9  Med: 17.3 Max: 119.9
Current: 13.74
5.9
119.9
EV-to-EBITDA 9.78
PRXL's EV-to-EBITDA is ranked higher than
75% of the 127 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 16.42 vs. PRXL: 9.78 )
Ranked among companies with meaningful EV-to-EBITDA only.
PRXL' s EV-to-EBITDA Range Over the Past 10 Years
Min: 4.3  Med: 11.1 Max: 19.5
Current: 9.78
4.3
19.5
PEG 0.85
PRXL's PEG is ranked higher than
92% of the 38 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.12 vs. PRXL: 0.85 )
Ranked among companies with meaningful PEG only.
PRXL' s PEG Range Over the Past 10 Years
Min: 0.24  Med: 1.43 Max: 15.64
Current: 0.85
0.24
15.64
Shiller P/E 37.25
PRXL's Shiller P/E is ranked higher than
55% of the 29 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 37.55 vs. PRXL: 37.25 )
Ranked among companies with meaningful Shiller P/E only.
PRXL' s Shiller P/E Range Over the Past 10 Years
Min: 23.29  Med: 53.67 Max: 124
Current: 37.25
23.29
124
Current Ratio 1.65
PRXL's Current Ratio is ranked lower than
69% of the 207 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.50 vs. PRXL: 1.65 )
Ranked among companies with meaningful Current Ratio only.
PRXL' s Current Ratio Range Over the Past 10 Years
Min: 1.21  Med: 1.63 Max: 3.36
Current: 1.65
1.21
3.36
Quick Ratio 1.65
PRXL's Quick Ratio is ranked lower than
63% of the 207 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.15 vs. PRXL: 1.65 )
Ranked among companies with meaningful Quick Ratio only.
PRXL' s Quick Ratio Range Over the Past 10 Years
Min: 1.21  Med: 1.63 Max: 3.36
Current: 1.65
1.21
3.36
Days Sales Outstanding 78.21
PRXL's Days Sales Outstanding is ranked lower than
65% of the 165 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 64.09 vs. PRXL: 78.21 )
Ranked among companies with meaningful Days Sales Outstanding only.
PRXL' s Days Sales Outstanding Range Over the Past 10 Years
Min: 61.59  Med: 84.65 Max: 149.34
Current: 78.21
61.59
149.34
Days Payable 12.66
PRXL's Days Payable is ranked lower than
94% of the 157 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 58.24 vs. PRXL: 12.66 )
Ranked among companies with meaningful Days Payable only.
PRXL' s Days Payable Range Over the Past 10 Years
Min: 7.12  Med: 13.49 Max: 17.87
Current: 12.66
7.12
17.87

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio 2.10
PRXL's 3-Year Average Share Buyback Ratio is ranked higher than
93% of the 131 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -5.50 vs. PRXL: 2.10 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
PRXL' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -7.3  Med: -1.3 Max: 2.8
Current: 2.1
-7.3
2.8

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 17.72
PRXL's Price/Tangible Book is ranked lower than
91% of the 198 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.57 vs. PRXL: 17.72 )
Ranked among companies with meaningful Price/Tangible Book only.
PRXL' s Price/Tangible Book Range Over the Past 10 Years
Min: 1.13  Med: 5.32 Max: 77.59
Current: 17.72
1.13
77.59
Price/Projected FCF 1.22
PRXL's Price/Projected FCF is ranked higher than
77% of the 83 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.16 vs. PRXL: 1.22 )
Ranked among companies with meaningful Price/Projected FCF only.
PRXL' s Price/Projected FCF Range Over the Past 10 Years
Min: 1.44  Med: 2.21 Max: 8.33
Current: 1.22
1.44
8.33
Price/DCF (Earnings Based) 0.71
PRXL's Price/DCF (Earnings Based) is ranked higher than
95% of the 21 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.74 vs. PRXL: 0.71 )
Ranked among companies with meaningful Price/DCF (Earnings Based) only.
N/A
Price/Median PS Value 1.15
PRXL's Price/Median PS Value is ranked lower than
61% of the 212 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.02 vs. PRXL: 1.15 )
Ranked among companies with meaningful Price/Median PS Value only.
PRXL' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.34  Med: 0.89 Max: 3.51
Current: 1.15
0.34
3.51
Price/Peter Lynch Fair Value 0.80
PRXL's Price/Peter Lynch Fair Value is ranked higher than
93% of the 27 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.66 vs. PRXL: 0.80 )
Ranked among companies with meaningful Price/Peter Lynch Fair Value only.
PRXL' s Price/Peter Lynch Fair Value Range Over the Past 10 Years
Min: 0.39  Med: 1.82 Max: 16.68
Current: 0.8
0.39
16.68
Price/Graham Number 3.85
PRXL's Price/Graham Number is ranked lower than
68% of the 81 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.92 vs. PRXL: 3.85 )
Ranked among companies with meaningful Price/Graham Number only.
PRXL' s Price/Graham Number Range Over the Past 10 Years
Min: 0.89  Med: 2.87 Max: 9.75
Current: 3.85
0.89
9.75
Earnings Yield (Greenblatt) (%) 7.30
PRXL's Earnings Yield (Greenblatt) (%) is ranked higher than
90% of the 258 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.94 vs. PRXL: 7.30 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
PRXL' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 0.8  Med: 5.8 Max: 16.9
Current: 7.3
0.8
16.9
Forward Rate of Return (Yacktman) (%) 28.12
PRXL's Forward Rate of Return (Yacktman) (%) is ranked higher than
87% of the 61 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9.70 vs. PRXL: 28.12 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
PRXL' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: 3.8  Med: 17.55 Max: 33.7
Current: 28.12
3.8
33.7

More Statistics

Revenue (TTM) (Mil) $2,418
EPS (TTM) $ 3.12
Beta0.62
Short Percentage of Float5.92%
52-Week Range $51.16 - 71.13
Shares Outstanding (Mil)53.27

Analyst Estimate

Jun17 Jun18 Jun19
Revenue (Mil $) 2,160 2,274 2,423
EPS ($) 3.72 4.21 5.21
EPS w/o NRI ($) 3.72 4.21 5.21
EPS Growth Rate
(3Y to 5Y Estimate)
9.55%
Dividends Per Share ($)
» More Articles for PRXL

Headlines

Articles On GuruFocus.com
Parexcel: Great Growth but a Tough Business Aug 17 2011 
PAREXEL International Corp. (PRXL) Senior VP & CFO James F Jr Winschel sells 12,920 Shares Mar 11 2011 
PAREXEL International Corp. (PRXL) Senior VP & CFO James F Jr Winschel sells 1,500 Shares Mar 11 2011 
PAREXEL International Corp. Reports Operating Results (10-Q) Feb 09 2011 
PAREXEL International Corp. Reports Operating Results (10-Q) Nov 09 2010 
PAREXEL International Corp. Reports Operating Results (10-K/A) Sep 09 2010 
PAREXEL International Corp. Reports Operating Results (10-K) Aug 27 2010 
PAREXEL International Corp. Reports Operating Results (10-Q) May 07 2010 
PAREXEL International Corp. (PRXL) Senior VP & CFO James F Jr Winschel sells 13,149 Shares Mar 12 2010 
PAREXEL International Corp. (PRXL) Senior VP & CFO James F Jr Winschel sells 15,600 Shares Mar 04 2010 

More From Other Websites
Lifshitz & Miller Law Firm Announces Investigation of Georgetown Bancorp, Inc., Lattice... Dec 01 2016
PAREXEL INTERNATIONAL CORP Financials Nov 23 2016
PAREXEL downgraded by Wells Fargo Nov 23 2016
PAREXEL International Announces $200 Million Accelerated Share Repurchase Program Nov 22 2016
PAREXEL INTERNATIONAL CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial... Nov 22 2016
PAREXEL International to Participate in Evercore ISI MedTools Conference Nov 16 2016
SHAREHOLDER ALERT: Lundin Law PC Announces an Investigation of PAREXEL International Corporation and... Nov 15 2016
Harwood Feffer LLP Announces Investigation of PAREXEL International Corporation Nov 15 2016
PAREXEL INTERNATIONAL CORP Files SEC form 8-K/A, Results of Operations and Financial Condition Nov 15 2016
IMPORTANT INVESTOR ALERT: Khang & Khang LLP Announces an Investigation of PAREXEL International... Nov 14 2016
Bragar Eagel & Squire, P.C. Is Investigating PAREXEL International Corporation (PRXL) on Behalf of... Nov 14 2016
EQUITY ALERT: Lundin Law PC Announces an Investigation of PAREXEL International Corporation and... Nov 14 2016
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Concerning Possible Violations... Nov 14 2016
IMPORTANT SHAREHOLDER ALERT: Khang & Khang LLP Announces an Investigation of PAREXEL International... Nov 14 2016
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of PAREXEL... Nov 14 2016
PAREXEL Launches IDMP-Focused Software and Service Solution Nov 14 2016
EQUITY ALERT: Goldberg Law PC Announces an Investigation of Claims against PAREXEL International... Nov 11 2016
Glancy Prongay & Murray LLP Commences Investigation on Behalf of PAREXEL International Corporation... Nov 11 2016
INVESTOR LOSS ALERT: Rosen Law Firm Announces Investigation of Securities Claims Against PAREXEL... Nov 11 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)